Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR1E | P28566 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | UGCG | Q16739 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3020553 | 0.99 | HTR2C (0.38) | HSD11B1HTR7HTR2AHTR2BHTR1A | |
| Hydrochloric Acid SCHEMBL3020550 | 0.99 | HTR2C (0.38) | HSD11B1HTR7HTR2AHTR2BHTR1A | |
| Hydrochloric Acid SCHEMBL3020548 | 0.99 | HTR2C (0.38) | HSD11B1HTR7HTR2AHTR2BHTR1A | |
| SCHEMBL8071550 | 0.88 | HSD11B1 (0.45) | HSD11B1HTR2AHTR2BHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL3023877 | 0.87 | HSD11B1 (0.44) | HSD11B1HTR2AHTR2BHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL3023874 | 0.87 | HSD11B1 (0.44) | HSD11B1HTR2AHTR2BHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL3023875 | 0.87 | HSD11B1 (0.44) | HSD11B1HTR2AHTR2BHTR1AHTR2C | |
| SCHEMBL8056572 | 0.81 | CHRNB2 (0.46) | HTR7HTR2AHTR2BHTR1AHTR6 | |
| SCHEMBL8070678 | 0.81 | CHRNB2 (0.36) | HTR7HTR2AHTR2BHTR1AHTR6 | |
| Hydrochloric Acid SCHEMBL3027043 | 0.80 | CHRNB2 (0.44) | HTR7HTR2AHTR2BHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | HSD11B1 95/4885HTR7 12/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.